pi-88

Small moleculeexperimental

Clinical trial activity

9 trials · 12 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Jul 1, 2001 (NCT00068172)

Timeline

2000s

Jan 1, 2001
Earliest Phase 1 Sponsor(trial)
Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Jan 1, 2007
Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Basic fibroblast growth factorINHIBITOR
FGF2 inhibitor
PI-88 acts as a competitive inhibitor of FGF-2 binding to cell surface and matrix HSPG.
- Fibroblast growth factor 2 (FGF2) ↗
HeparanaseINHIBITOR
HPSE inhibitor
- Heparanase (HPSE) ↗
Acidic fibroblast growth factorINHIBITOR
FGF1 inhibitor
- Fibroblast growth factor 1 (FGF1) ↗
Vascular endothelial growth factor AINHIBITOR
VEGFA inhibitor
- Vascular endothelial growth factor A (VEGFA) ↗

Chemistry & pharmacology

Loading structure…

SMILES

O=P(O)(O)OC[C@H]1O[C@H](O[C@@H]2[C@H](OS(=O)(=O)O)[C@@H](O[C@@H]3[C@H](OS(=O)(=O)O)[C@@H](O[C@@H]4[C@H](OS(=O)(=O)O)[C@@H](O[C@@H]5[C@@H](OS(=O)(=O)O)O[C@H](COS(=O)(=O)O)[C@@H](OS(=O)(=O)O)[C@@H]5OS(=O)(=O)O)O[C@H](COS(=O)(=O)O)[C@H]4OS(=O)(=O)O)O[C@H](COS(=O)(=O)O)[C@H]3OS(=O)(=O)O)O[C@H](COS(=O)(=O)O)[C@H]2OS(=O)(=O)O)[C@@H](OS(=O)(=O)O)[C@@H](OS(=O)(=O)O)[C@@H]1OS(=O)(=O)O

Mol. weight: 2189.72 g/mol
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

ChEMBLCHEMBL4297163 ↗
ChEMBLCHEMBL1615835 ↗

Also known as

heparanase inhibitor pi-88
muparfostat
muparfostat
muparfostat
muparfostat
phosphomannopentaose sulfate
pi-88
pi-88
pi-88
pi-88
pi-88
pi88 cpd

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT01402908	Phase 3	Aug 1, 2011	Medigen Biotechnology Corporation, National Taiwan University
NCT00568308	Phase 3	Dec 1, 2007	Progen Pharmaceuticals, The University of Hong Kong
NCT00268593	Phase 2	Aug 1, 2005	Aventis, Northern Sydney and Central Coast Area Health Service, Progen Pharmaceuticals, Sydney Haematology and Oncology Clinics, University of Sydney
NCT00130442	Phase 2	Jun 1, 2005	Medigen Biotechnology Corporation, Progen Pharmaceuticals, Sydney Cancer Centre, University of Sydney, University of Western Australia
NCT00247728	Phase 2	Jun 1, 2004	Medigen Biotechnology Corporation, National Taiwan University, Progen Pharmaceuticals
NCT00103389	Phase 2	Feb 1, 2004	Medigen Biotechnology Corporation, Progen Pharmaceuticals, University of Sydney
NCT00097851	Phase 2	Feb 1, 2004	Medigen Biotechnology Corporation, University of Melbourne, University of Sydney
NCT00073892	Phase 1/Phase 2 (Phase 2)	Jan 1, 2004	Medigen Biotechnology Corporation, Progen Pharmaceuticals, University of Colorado, Denver
NCT00068172	Phase 1/Phase 2 (Phase 2)	Jul 1, 2001	Medigen Biotechnology Corporation

Showing 9 of 9 trials

Page 1 / 1

Organizations

Research & Development (12)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Medigen Biotechnology Corporation	For profit	7	6	2	2001
Progen Pharmaceuticals	For profit	6	3	2	2004
University of Sydney	Academic/Hospital	4	0	1	2004
National Taiwan University	Academic/Hospital	2	0	2	2004
Aventis	For profit	1	0	1	2005
Northern Sydney and Central Coast Area Health Service	Academic/Hospital	1	0	1	2005
Sydney Cancer Centre	Academic/Hospital	1	0	1	2005
Sydney Haematology and Oncology Clinics	Academic/Hospital	1	0	1	2005
The University of Hong Kong	Academic/Hospital	1	0	1	2007
University of Colorado, Denver	Academic/Hospital	1	0	1	2004
University of Melbourne	Academic/Hospital	1	0	1	2004
University of Western Australia	Academic/Hospital	1	0	1	2005

12 organizations

Page 1 / 1